COVID-19 pandemic has caused a tremendous shift in medical focus from almost every disorder to COVID-19 treatment. It has been observed that each step in the cancer management pathway has been disrupted by the COVID-19 virus that is the diagnosis, screening, treatment, research and development. This pandemic will most certainly continue to have an impact on cancer patients and their treatment for the foreseeable future.
Through this whitepaper, we have enlightened about the effect of COVID-19 on oncology diagnosis, screening, patient outcomes, treatment modalities, clinical trials, availability of drugs, clinical advancements and what pharmaceutical companies are doing to fight with this situation.
Download Whitepaper
PDF not available.
